The IMPROVE Consortium was established to evaluate whether intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine (DP), with or without azithromycin (AZ), is a viable alternative to current policy for the prevention of malaria and sexually transmitted and reproductive tract infections (STIs/RTIs) in pregnancy in high SP resistance areas in Kenya, Malawi, and Tanzania.
The Consortium comprises two multicentre trials, one conducted among HIV-uninfected women (IMPROVE) and one among HIV-infected women taking co-trimoxazole (IMPROVE-2).
0
%EF%B9%96itok=JPevQooO×tamp=1548756491.jpeg)
